Previous 10 | Next 10 |
2023-07-23 00:51:26 ET Summary Denali Therapeutics is a promising underdog in the biotech sector, focusing on neurodegenerative diseases, with significant investments in scientific exploration and a robust financial health despite net losses. The company's pipeline includes seven ...
2023-07-17 00:45:27 ET Summary Denali Therapeutics reported Q1 2023 losses of $109.8 million, up from $65.2 million in Q1 2022, with reduced revenue from partnerships with Takeda and Biogen. The company's Phase 1/2 trial for DNL310, a treatment for Hunter syndrome, showed a signif...
2023-06-29 05:13:37 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Longevity efforts are forefront of the news cycle today, due in large part to recent coverage of tech billionaire Bryan Johnson’s unique strategy to delay aging . This has investors ...
Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs PR Newswire Empress's Chemilogics™ product platform creates small molecule drugs quickly and cost-effectively Th...
Interim results demonstrate average reduction of 64% (p <0.001) from baseline in serum NfL after 2 years of dosing with DNL310 in Phase 1/2 study FDA has recommended assessment of NfL, a marker of neuroaxonal damage, as a possible biomarker in MPS II Additional interim data from the ...
2023-06-05 10:26:34 ET Denali Therapeutics ( NASDAQ: DNLI ) announced Monday that the company and its partner Biogen ( BIIB ) have decided to discontinue a Phase 3 trial for Parkinson’s disease (PD) candidate BIIB122 (DNL151). The company said the decision follows a r...
Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry PR Newswire The company's MIMiC™ platform drives unprecedented insights into molecular interactions to design new biomolecules precisely tuned for therapeutic benefi...
2023-05-15 16:31:43 ET Shares of Denali Therapeutics (NASDAQ: DNLI) were up more than 14% Monday afternoon. The company reported first-quarter earnings a week ago, and three analysts recently maintained their buy ratings on the clinical-stage biotech company, which focuses on th...
2023-05-08 17:13:08 ET Denali Therapeutics press release ( NASDAQ: DNLI ): Q1 GAAP EPS of -$0.80 misses by $0.10 . Revenue of $35.14M (-16.6% Y/Y) beats by $5.26M . For further details see: Denali Therapeutics GAAP EPS of -$0.80 misses by $0.10, revenue o...
SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal sto...
News, Short Squeeze, Breakout and More Instantly...
Denali Therapeutics Inc. Company Name:
DNLI Stock Symbol:
NASDAQ Market:
Denali Therapeutics Inc. Website:
2024-07-10 22:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
START is a pilot program newly launched jointly by the FDA CDER and CBER divisions to further accelerate the development of novel drug and biological products for rare diseases DNL126 was selected as one of three CDER-regulated products based on eligibility criteria including the potentia...
2024-05-10 10:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...